Table 8 maspin expression in head and neck cancers
From: Role of maspin in cancer
Authors | Year | N. patients | Maspin expression | Clinical pathological features/prognosis |
|---|---|---|---|---|
Yoshizawa et al. | 2011 | 54 (OSCC) | 64.8% positive maspin | Positive maspin = 77.8% OS |
35.2% negative maspin | Negative maspin = 29.4% OS | |||
Yoshizawa et al. | 2009 | 71 (OSCC) | 64.8% positive maspin | Positive maspin = 100% low grade, 93.3% no lymphnode metastasis, better OS |
Iezzi et al. | 2007 | 89 (OSCC) | Not found | Positive maspin = low grade, negative lymphnode, high stage(?) |
Marioni et al. | 2008 | 56 (OSCC) | 58.9% positive maspin | |
5.3 % positive nucleus | ||||
1.8% positive cytoplasm-nucleus | ||||
51.8% positive cytoplasm | Positive cytoplasmic maspin = 61% pN0 and 33% pN+ | |||
41.1% negative maspin | ||||
Marioni et al. | 2011 | 68 (laryngeal cancer) | Not found | Positive nucleus = 22.7% lower recurrence and PFS: 44.5 ± 27.5 months |
Positive cytoplasm and cytoplasm-nucleus = 44.6% longer recurrence and PFS: 34 ± 27.5 months |